AllAnalyst Report
logoMorningstarJanuary 20, 2021

Exact Sciences Corporation: Liquid Biopsy Creates Large Opportunities for Testmakers, Including Potential First Mover Illumina

Symbols
EXAS
Sector(s)
Healthcare
Rating
Current Price
$70.00
Fair Value
Economic Moat
Stewardship
Summary

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Analyst Profile

Aaron Degagne

Equity Analyst
Aaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.